Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine

Journal of Nuclear Medicine

Volumn 48, Issue 6, 2007, Pages 973-980

  Beck, Roswitha ^a   Röper, Barbara ^a   Carlsen, Janette Maria ^a   Huisman, Marc Cornelis ^a   Lebschi, Julia Aloisia ^a   Andratschke, Nicolaus ^a   Picchio, Maria ^b   Souvatzoglou, Michael ^a   Machulla, Mans Jürgen ^c   Piert, Morand ^d,e  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

EMT6; FAZA; Radiochemotherapy; Tirapazamine; Tumor hypoxia

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; FLUORINE 18; FLUOROAZOMYCIN ARABINOSIDE F 18; TIRAPAZAMINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORINE; FLUOROAZOMYCIN ARABINOSIDE; NITROIMIDAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HYPOXIA; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NUDE MOUSE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; ANIMAL; CANCER TRANSPLANTATION; CELL HYPOXIA; EXPERIMENTAL NEOPLASM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; SCINTISCANNING; TUMOR CELL LINE; WHOLE BODY IMAGING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; FLUORINE RADIOISOTOPES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES; WHOLE BODY IMAGING;

EID: 34250326197     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.038570     Document Type: Article

References (43)

1. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515.
2. Molls M, Feldmann HJ, Fuller J. Oxygenation of locally advanced recurrent rectal cancer, soft tissue sarcoma and breast cancer. Adv Exp Med Biol. 1994;345:459-463.
3. Molls M, Stadler P, Becker A, Feldmann HJ, Dunst J. Relevance of oxygen in radiation oncology: mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol. 1998;174(suppl 4):13-16.
4. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002;7:492-508.
5. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53:113-117.
6. Bottaro DP, Liotta LA. Cancer: out of air is not out of action. Nature. 2003;423:593-595.
7. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347-361.
8. Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem. 2001;36:577-595.
9. Dorie MJ, Brown JM. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol. 1997;39:361-366.
10. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res. 2003;9:5714-5720.
11. Lee DJ, Trotti A, Spencer S, et al. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radial Oncol Biol Phys. 1998;42:811-815.
12. Miller VA, Ng KK, Grant SC, et al. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 1997;8:1269-1271.
13. von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT 1 study group - Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol. 2000;18:1351-1359.
14. Wouters BG, Wang LH, Brown JM. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol. 1999;10(suppl 5):S29-S33.
15. 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106-113.
16. 18F-FAZA, a new tracer for hypoxia [abstract]. J Nucl Med. 2002;43(suppl):364P.
17. 18F]FAZA: reaction parameters and automation. Appl Radial Isot. 2005;62:897-901.
18. Rockwell SC, Kallman RF, Fajardo LF. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst. 1972;49:735-749.
19. Papadopoulou MV, Ji M, Bloomer WD. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol. 2001;48:160-168.
20. Röper B, Beck R, Andratschke N, et al. Volumetry of experimental tumors: advantage of ultrasound compared to standard approaches [in German] [abstract]. Strahlenther Onkol. 2005;181:103.
21. Papadopoulou MV, Ji M, Bloomer WD, Hollingshead MG. Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts. J Exp Ther Oncol. 2002;2:298-305.
22. Surti S, Karp JS, Perkins AE, et al. Imaging performance of A-PET: a small animal PET camera. IEEE Trans Med Imaging. 2005;24:844-852.
23. Daube-Witherspoon M, Matej S, Karp J, Lewitt R. A row-action alternative to the EM algorithm for maximizing likelihoods in emission tomography. IEEE Trans Nucl Sci. 2001;48:24-30.
24. Tai C, Chatziioannou A, Siegel S, et al. Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol. 2001;46:1845-1862.
25. Corry J, Rischin D. Strategies to overcome accelerated repopulation and hypoxia: What have we learned from clinical trials? Semin Oncol. 2004;31:802-808.
26. Emmenegger U, Morton GC, Francia G, et al. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res. 2006;66:1664-1674.
27. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098-2104.
28. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19:535-542.
29. Craighead PS, Pearcey R, Stuart G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int J Radial Oncol Biol Phys. 2000;48:791-795.
30. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 1990;50:7745-7749.
31. 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-1238.
32. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-260.
33. Grosu AL, Piert M, Weber WA, et al. Positron emission tomography for radiation treatment planning. Strahlemher Onkol. 2005;181:483-499.
34. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anti-cancer Drug Des. 1998;13:519-528.
35. 64Cu-ATSM: a comparison study with FDG. Nucl Med Biol. 2003;30:529-534.
36. 2 measurements in murine tumors. Int J Radiat Oncol Biol Phys. 2005;62:854-861.
37. Brown JM, Twentyman PR, Zamvil SS. Response to the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay, and tumor control), chemotherapeutic agents, and activated macrophages. J Natl Cancer Inst. 1980;64:605-611.
38. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys. 1984;10:695-712.
39. 125I-gluco-RGD and HIF-1 expression in a murine tumor hypoxia model [abstract]. J Nucl Med. 2005;46(suppl):126P.
40. Greer S, Schwade J, Marion HS. Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation. Int J Radiat Oncol Biol Phys. 1995;32:1059-1069.
41. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography. 1. Effect of object size. J Comput Assist Tomogr. 1979;3:299-308.
42. Lamare F, Turzo A, Bizais Y, Le Rest CC, Visvikis D. Validation of a Monte Carlo simulation of the Philips Allegro/GEMINI PET systems using GATE. Phys Med Biol. 2006;51:943-962.
43. Hwang D, Zeng GL. A new simple iterative reconstruction algorithm for SPECT transmission measurement. Med Phys. 2005;32:2312-2319.